RDY Market Capitalization from 2010 to 2024
| RDY Stock | USD 14.08 0.06 0.42% |
Check Dr Reddys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dr Reddys' main balance sheet or income statement drivers, such as Interest Expense of 1.8 B, Total Revenue of 293.1 B or Gross Profit of 171.8 B, as well as many indicators such as Price To Sales Ratio of 3.91, Dividend Yield of 0.0061 or PTB Ratio of 3.89. RDY financial statements analysis is a perfect complement when working with Dr Reddys Valuation or Volatility modules.
RDY | Market Capitalization |
Latest Dr Reddys' Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Dr Reddys Laboratories over the last few years. It is Dr Reddys' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dr Reddys' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 11.94 B | 10 Years Trend |
|
Market Cap |
| Timeline |
RDY Market Capitalization Regression Statistics
| Arithmetic Mean | 224,280,589,603 | |
| Geometric Mean | 113,128,702,258 | |
| Coefficient Of Variation | 153.33 | |
| Mean Deviation | 224,463,670,395 | |
| Median | 103,458,095,374 | |
| Standard Deviation | 343,899,041,702 | |
| Sample Variance | 118266550883.6T | |
| Range | 1.1T | |
| R-Value | 0.66 | |
| Mean Square Error | 71759317258.5T | |
| R-Squared | 0.44 | |
| Significance | 0.01 | |
| Slope | 50,809,890,348 | |
| Total Sum of Squares | 1655731712370T |
RDY Market Capitalization History
About Dr Reddys Financial Statements
Dr Reddys investors use historical fundamental indicators, such as Dr Reddys' Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Dr Reddys. Please read more on our technical analysis and fundamental analysis pages.
Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 24795 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.